Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia
Open Access
- 15 June 2021
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 10 (6) , 956
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease with a high relapse rate. Cytokine receptor targeted therapies are therapeutically attractive but are subject to resistance-conferring mutations. Likewise, targeting downstream signaling pathways has been difficult. Recent success in the development of synergistic combinations has provided new hope for refractory AML patients. While generally not efficacious as monotherapy, BH3 mimetics are very effective in combination with chemotherapy agents. With this in mind, we further explored novel BH3 mimetic drug combinations and showed that pimozide cooperates with mTOR inhibitors and BH3 mimetics in AML cells. The three-drug combination was able to reach cells that were not as responsive to single or double drug combinations. In Flt3-internal tandem duplication (ITD)-positive cells, we previously showed pimozide to be highly effective when combined with imipramine blue (IB). Here, we show that Flt3-ITD+ cells are sensitive to an IB-induced dynamin 1-like (Drp1)-p38-ROS pathway. Pimozide contributes important calcium channel blocker activity converging with IB on mitochondrial oxidative metabolism. Overall, these data support the concept that antioxidants are a double-edged sword. Rationally designed combination therapies have significant promise for further pre-clinical development and may ultimately lead to improved responses.Keywords
Funding Information
- National Institutes of Health (1R01HL152131-01)
- AFLAC Cancer and Blood Disorders Center (Pilot grant, no number)
This publication has 39 references indexed in Scilit:
- FLT3 inhibition: a moving and evolving target in acute myeloid leukaemiaLeukemia, 2012
- The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 MutationsGenes & Cancer, 2012
- Anti-Invasive Adjuvant Therapy with Imipramine Blue Enhances Chemotherapeutic Efficacy Against GliomaScience Translational Medicine, 2012
- The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activityLeukemia, 2011
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsBlood, 2011
- The role of Stat5 transcription factors as tumor suppressors or oncogenesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2011
- Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycinLeukemia, 2010
- STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative diseaseBlood, 2010
- IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survivalBlood, 2008
- BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blastsLeukemia, 2007